Compare Quest Diagnostics Inc (DGX) vs Estee Lauder Companies Inc (EL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Estee Lauder Companies Inc — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while Estee Lauder Companies Inc trades at $81.04 (market cap $29.25B). The key difference: Estee Lauder Companies Inc is the larger of the two by market cap, and Estee Lauder Companies Inc pays the higher dividend (1.73%). Which is the better fit depends on your goals.
| DGX | EL | |
|---|---|---|
Market Cap | $22.80B | $29.25B |
Sector | Health | Consumer Staples |
52-Week High | $216.02 | $119.61 |
52-Week Low | $166.42 | $67.23 |
Enterprise Value | $28.82B | $35.43B |
Dividend Yield | 1.67% | 1.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Estée Lauder (EL) trades at $81.15, down 1.83% on the day, with a bearish technical outlook and mixed fundamentals. The stock shows negative net income and declining revenue trends, though recent quarters have beaten EPS estimates. Analyst consensus is divided with a $90.60 price target, while technical indicators point to support near $80.
Outlook remains cautious due to profitability challenges and competitive pressures, but potential upside exists if cost controls and innovation drive margin recovery. Key risks include sustained earnings pressure and macroeconomic sensitivity in the beauty sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →
